2-氟-5-(三氟甲基)苯乙腈 | 220227-59-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氟-5-(三氟甲基)苯乙腈
• 中文别名: 2-氟-5-三氟甲基苯乙腈
• 英文名称: (2-fluoro-5-trifluoromethyl-phenyl)-acetonitrile
• 英文别名: (2-fluoro-5-trifluoromethylphenyl)-acetonitrile；2-fluoro-5-trifluoromethyl-phenylacetonitrile；2-Fluoro-5-(Trifluoromethyl)Phenylacetonitrile；2-[2-fluoro-5-(trifluoromethyl)phenyl]acetonitrile
• CAS: 220227-59-8
• 化学式: C₉H₅F₄N
• mdl: MFCD00061180
• 分子量: 203.139
• InChiKey: UTHSCSXLGDJQGQ-UHFFFAOYSA-N

物化性质

• 沸点：
  209.6±35.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  TOXIC
• 危险品标志：
  T
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  UN 3276
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  2-氟-5-(三氟甲基)苯乙腈 在 硼烷四氢呋喃络合物 、 甲醇 作用下， 以 四氢呋喃 为溶剂， 反应 24.42h， 生成 2-氟-5-(三氟甲基)苯乙胺
  参考文献：
  名称：

  Indole, indazole and indoline derivatives as CETP inhibitors

  摘要：

  本发明涉及以下式(I)的化合物： 其中-X-Y-, R1至R11和n如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物对于治疗和/或预防通过CETP抑制剂介导的疾病是有用的。

  公开号：

  US20060030613A1

文献信息

• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
• Novel fluorescent carbazole derivative
  申请人：——

  公开号：US20030023099A1

  公开（公告）日：2003-01-30

  The object of this invention is to provide an illuminant, which can easily be produced at low cost. This invention is a carbazole derivative luminescent compound having a carbazole ring skeleton, to the nitrogen atom of which is attached an electron-donating group, and to the carbon atom of which is attached an electron-attracting group at the third position to the nitrogen atom.

  这项发明的目的是提供一种发光剂，可以以低成本轻松生产。这项发明是一种具有咔唑环骨架的咔唑衍生物发光化合物，其中咔唑环骨架的氮原子上连接有一个给电子基团，而连接到该氮原子的第三位置的碳原子上连接有一个吸电子基团。
• [EN] NOVEL POTASSIUM CHANNEL INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DU CANAL POTASSIQUE
  申请人：SANIONA AS

  公开号：WO2022063767A1

  公开（公告）日：2022-03-31

  The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.

  本发明涉及新型化合物、包含这些化合物的制药组合物及其用于治疗、缓解或预防与钾通道活性相关的疾病或疾病的方法。
• Non-steroidal progesting
  申请人：Schering AG

  公开号：US20030232824A1

  公开（公告）日：2003-12-18

  The present invention relates to non-steroidal progestins of the general formula (I) 1 wherein R 1 and R 2 are independently of each other —H or —F, R 3 is —CH 3 or —CF 3 , and Ar is 2 or a pharmaceutically acceptable derivative or analogue thereof. These progestins are suitable for selectively modulating progesterone receptor mediated effects in different target tissues, particularly in uterine tissue versus breast tissue. Therefore, the progestins of the present invention, optionally in combination with estrogens, may be used for contraception (in particular in estrogen-free oral contraceptives), hormone replacement therapy and the treatment of gynecological disorders. The present invention furthermore relates to methods for selectively modulating progesterone receptor mediated effects in different target tissues or organs.

  本发明涉及一般式(I)的非甾体孕酮类似物，其中R1和R2分别为—H或—F，R3为—CH3或—CF3，Ar为2或其药物可接受的衍生物或类似物。这些孕酮类似物适用于在不同的靶组织中选择性调节孕激素受体介导的效应，特别是在子宫组织与乳腺组织中。因此，本发明的孕酮类似物，可选配雌激素，可用于避孕（特别是在无雌激素口服避孕药中）、激素替代疗法和治疗妇科疾病。本发明还涉及在不同的靶组织或器官中选择性调节孕激素受体介导的效应的方法。
• 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders
  申请人：Schering Aktiengesellschaft

  公开号：EP1344776A1

  公开（公告）日：2003-09-17

  The present invention relates to non-steroidal progestins of the general formula (I) wherein R1 and R2 are independently of each other -H or -F, R3 is -CH3 or -CF3, and Ar is or a pharmaceutically acceptable derivative or analogue thereof. These progestins are suitable for selectively modulating progesterone receptor mediated effects in different target tissues, particularly in uterine tissue versus breast tissue. Therefore, the progestins of the present invention, optionally in combination with estrogens, may be used for contraception, hormone replacement therapy and the treatment of gynecological disorders. The present invention furthermore relates to methods for selectively modulating progesterone receptor mediated effects in different target tissues or organs.

  本发明涉及通式（I）的非类固醇孕激素，其中R1和R2独立地为-H或-F，R3为-CH3或-CF3，而Ar为或其药物可接受的衍生物或类似物。这些孕激素适用于在不同的靶组织中选择性调节孕激素受体介导的效应，特别是在子宫组织与乳腺组织中。因此，本发明的孕激素，可选择性与雌激素联合使用，可用于避孕、激素替代疗法以及妇科疾病的治疗。本发明还涉及在不同的靶组织或器官中选择性调节孕激素受体介导的效应的方法。